Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression - 02/09/11
Abstract |
Pyoderma gangrenosum is a rare, destructive, neutrophilic dermatosis, the origin of which remains largely obscure. The ulcerative variant of this inflammatory disorder causes painful, necrotic, rapidly enlarging ulcers. Because of pathergy, many clinicians avoid managing these nonhealing ulcers with aggressive surgical debridement and autologous grafts. This article proposes that the application of an allogeneic cultured human skin equivalent (Graftskin) not only circumvents this problem, but also hastens re-epithelialization of the ulcer bed. An added benefit of the possible improvement of the cosmetic appearance of the final scar by preventing severe wound contracture is also postulated. We report a newly diagnosed case of ulcerative pyoderma gangrenosum; the use of bioengineered skin as an adjunct to concurrent immunosuppressive therapy with cyclosporine hastened the healing and diminished pain in a rapidly enlarging leg ulcer. Within 2 weeks, the ulcer was 30% to 40% healed, achieving 100% re-epithelialization within 6 weeks. (J Am Acad Dermatol 2001;44:61-6.)
Le texte complet de cet article est disponible en PDF.Plan
Funding sources: none; disclosure statement: Vincent Falanga, MD, FACP, has been and is currently a clinical investigator of Graftskin. The other authors have no conflict of interest to declare. All authors have indicated no significant financial interests with commercial supporters. |
|
Reprint requests: Vincent Falanga, MD, FACP, Chairman and Professor of Dermatology, Department of Dermatology and Skin Surgery, Roger Williams Medical Center, Boston University School of Medicine, 50 Maude St, Providence, RI 02908. E-mail: asana@sympatico.ca. |
|
J Am Acad Dermatol 2001;44:61-6. |
Vol 44 - N° 1
P. 61-66 - janvier 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?